Sofinnova Investments’s Cymabay Therapeutics CBAY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-11,040
Closed -$165K 82
2023
Q3
$165K Buy
+11,040
New +$146K 0.01% 64

Other funds holding CBAY

Sofinnova Investments's CBAY Position: Q1 2024 in Review

Sofinnova Investments sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 1,411,769 shares — an estimated $33.3M sold.

Sofinnova Investments first reported a position in CBAY in Q4 2023 and held it in 1 quarter. The position peaked at $33.3M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Sofinnova Investments reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Sofinnova Investments sold 1,411,769 Cymabay Therapeutics shares in Q1 2024, an estimated $33.3M.
  • Sofinnova Investments first reported a position in Cymabay Therapeutics in Q4 2023 and held it in 1 quarter.
  • Sofinnova Investments's Cymabay Therapeutics position peaked at $33.3M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Sofinnova Investments's 13F filing for Q1 2024, filed 15 May 2024.